Float Short %

2.96

Margin Of Safety %

-3

Put/Call OI Ratio

0.66

EPS Next Q Diff

1.29

EPS Last/This Y

3.34

EPS This/Next Y

2.2

Price

135.42

Target Price

167.88

Analyst Recom

1.34

Performance Q

13.69

Relative Volume

0.59

Beta

0.28

Ticker: NBIX

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-07-28	NBIX	133.73	0.64	0.78	7284
2025-07-29	NBIX	134.19	0.65	1.77	7331
2025-07-30	NBIX	136.75	0.66	0.17	7424
2025-07-31	NBIX	128.23	0.59	4.33	8431
2025-08-01	NBIX	128.84	0.70	0.18	9490
2025-08-04	NBIX	127.6	0.68	2.77	9753
2025-08-05	NBIX	128.39	0.69	2.09	9790
2025-08-06	NBIX	128.35	0.69	7.00	9811
2025-08-07	NBIX	125.59	0.69	6.02	9827
2025-08-08	NBIX	124.94	0.73	1.26	10133
2025-08-11	NBIX	123.95	0.73	0.56	10164
2025-08-12	NBIX	128.95	0.73	0.02	10214
2025-08-13	NBIX	131.57	0.73	0.48	10232
2025-08-14	NBIX	131.31	0.73	1.00	10234
2025-08-15	NBIX	132.96	0.74	0.00	10838
2025-08-18	NBIX	133.18	0.68	0.09	6091
2025-08-19	NBIX	132.76	0.68	0.00	6100
2025-08-20	NBIX	133.27	0.67	0.63	6130
2025-08-21	NBIX	135.28	0.67	0.18	6138
2025-08-22	NBIX	135.44	0.66	0.06	6169
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-07-28	NBIX	133.95	-9.8	136.0	6.07
2025-07-29	NBIX	134.19	-9.8	129.0	6.07
2025-07-30	NBIX	136.76	-9.8	139.7	6.07
2025-07-31	NBIX	128.23	-7.7	84.0	6.09
2025-08-01	NBIX	128.91	-7.7	132.5	6.09
2025-08-04	NBIX	128.04	16.7	172.2	6.80
2025-08-05	NBIX	128.39	16.7	178.6	6.80
2025-08-06	NBIX	128.49	15.5	160.2	6.72
2025-08-07	NBIX	125.60	15.5	143.9	6.72
2025-08-08	NBIX	125.01	15.6	156.4	6.74
2025-08-11	NBIX	123.99	15.6	153.8	6.74
2025-08-12	NBIX	128.95	15.6	188.7	6.74
2025-08-13	NBIX	131.62	15.6	174.9	6.74
2025-08-14	NBIX	131.34	15.6	158.2	6.74
2025-08-15	NBIX	132.91	15.6	168.5	6.74
2025-08-18	NBIX	133.18	15.6	161.2	6.74
2025-08-19	NBIX	132.81	15.6	158.0	6.74
2025-08-20	NBIX	133.18	15.6	161.7	6.74
2025-08-21	NBIX	135.32	15.6	170.9	6.74
2025-08-22	NBIX	135.42	15.6	160.5	6.74
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-07-28	NBIX	-8.55	-0.82	3.39
2025-07-29	NBIX	-8.55	-0.82	3.39
2025-07-30	NBIX	-4.92	-0.82	3.39
2025-07-31	NBIX	-4.92	-0.82	3.39
2025-08-01	NBIX	-4.92	-0.82	3.39
2025-08-04	NBIX	-4.91	-0.77	3.38
2025-08-05	NBIX	-4.56	-0.77	3.38
2025-08-06	NBIX	-4.56	-0.77	3.38
2025-08-07	NBIX	-4.56	-0.77	3.38
2025-08-08	NBIX	-4.56	-0.77	3.38
2025-08-11	NBIX	-4.56	-0.74	3.38
2025-08-12	NBIX	-7.26	-0.74	2.98
2025-08-13	NBIX	-7.05	-0.74	2.98
2025-08-14	NBIX	-7.05	-0.74	2.98
2025-08-15	NBIX	-6.08	-0.74	2.98
2025-08-18	NBIX	-6.08	-0.06	2.98
2025-08-19	NBIX	-6.08	-0.06	2.96
2025-08-20	NBIX	-7.77	-0.06	2.96
2025-08-21	NBIX	-7.77	-0.06	2.96
2025-08-22	NBIX	-7.77	-0.06	2.96
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

1.06

Avg. EPS Est. Current Quarter

2.09

Avg. EPS Est. Next Quarter

2.35

Insider Transactions

-7.77

Institutional Transactions

-0.06

Beta

0.28

Average Sales Estimate Current Quarter

745

Average Sales Estimate Next Quarter

784

Fair Value

131.98

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

14.3

Max Drawdown 5-Year %

-42.9

Target Price

167.88

P/E

39.97

Forward P/E

20.43

PEG

1.05

P/S

5.35

P/B

4.98

P/Free Cash Flow

25.41

EPS

3.39

Average EPS Est. Cur. Y

6.74

EPS Next Y. (Est.)

8.94

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

13.88

Relative Volume

0.59

Return on Equity vs Sector %

-11.8

Return on Equity vs Industry %

5.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.65

EBIT Estimation

160.5

Neurocrine Biosciences, Inc.

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 1800

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

stock quote shares NBIX – Neurocrine Biosciences, Inc. Stock Price stock today

news today NBIX – Neurocrine Biosciences, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch NBIX – Neurocrine Biosciences, Inc. yahoo finance google finance

stock history NBIX – Neurocrine Biosciences, Inc. invest stock market

stock prices NBIX premarket after hours

ticker NBIX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: NBIX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y